Carvedilol in hypertension treatment

References

• AgrawalBWolfKBergerAEffect of antihypertensive treatment on qualitative estimates of microalbuminuriaJ Hum Hypertens19961055158895040
   PubMedGoogle Scholar
• BakrisGLFonsecaVKatholiREMetabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialJAMA200429222273615536109
   PubMed Web of Science ®Google Scholar
• BenjaminEJLevyDWhy is left ventricular hypertrophy so predictive of morbidity and mortality?Am J Med Sci19993171687510100690
   PubMed Web of Science ®Google Scholar
• BlackHRSicaDAA modern perspective on beta-blocker use in hypertension: clinical trials and their influence on clinical practiceJ Clin Hypertens (Greenwich)200791018
   Google Scholar
• BrookRDMechanism of differential effects of antihypertensive agents on serum lipidsCurr Hypertens Rep20002370710981172
   PubMedGoogle Scholar
• CarlbergBSamuelssonOLindholmLHAtenolol in hypertension: is it a wise choice?Lancet20043641684915530629
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA200328925607212748199
   PubMed Web of Science ®Google Scholar
• CollinsRPetoRMacMahonSBlood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological contextLancet1990335827381969567
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DahlofBLindholmLHHanssonLMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)Lancet1991338128151682683
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• DupontAGEffects of carvedilol on renal functionEur J Clin Pharmacol199038Suppl 2S961001974513
   PubMedGoogle Scholar
• DupontAGVan derNPTaeymansYEffect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertensionJ Cardiovasc Pharmacol198710Suppl 11S130S62454359
   PubMedGoogle Scholar
• ESH-ESC Guidelines Committee2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• FlegJLSchulmanSO’ConnorFEffects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exerciseCirculation1994902333417955191
   PubMed Web of Science ®Google Scholar
• FleischmannEHSchmiederREAre all antihypertensive drug classes equal in reducing left ventricular hypertrophy?Curr Cardiol Rep20024474812379166
   PubMedGoogle Scholar
• FogariRZoppiAPolettiLSexual activity in hypertensive men treated with valsartan or carvedilol: a crossover studyAm J Hypertens200114273111206674
   PubMed Web of Science ®Google Scholar
• FrishmanWHCarvedilolN Engl J Med19983391759659845712
   PubMed Web of Science ®Google Scholar
• GalzeranoDTammaroPdelVLThree-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal studyAm J Hypertens2005181563916364826
   PubMed Web of Science ®Google Scholar
• GiuglianoDAcamporaRMarfellaRMetabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trialAnn Intern Med199712695599182472
   PubMed Web of Science ®Google Scholar
• GossePLeft ventricular hypertrophy as a predictor of cardiovascular riskJ Hypertens Suppl200523S27S3315821448
   PubMedGoogle Scholar
• HaenniALithellHTreatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertensionMetabolism199443455618159103
   PubMed Web of Science ®Google Scholar
• HannedoucheTLandaisPGoldfarbBRandomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failureBMJ199430983377950612
   PubMedGoogle Scholar
• HendersonLSTeneroDMBaidooCAPharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertensionAm J Cardiol20069817L26L
   PubMed Web of Science ®Google Scholar
• JacobSRettKWicklmayrMDifferential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol studyJ Hypertens199614489948761899
   PubMed Web of Science ®Google Scholar
• KaplanNZipesDLibbyPBonowRSystemic hypertension: mechanisms and diagnosisBraunwald’s Heart Disease. A Textbook of Cardiovascular Medicine2005a7Philadelphia, PensylvaniaElsevier Saunders95987
   Google Scholar
• KaplanNZipesDLibbyPBonowRSystemic Hypertension: TherapyBraunwald’s Heart Disease. A Textbook of Cardiovascular Medicine2005b7Philadelphia, PensylvaniaElsevier Saunders9891012
   Google Scholar
• KasiskeBLMaJZKalilRSEffects of antihypertensive therapy on serum lipidsAnn Intern Med1995122133417992988
   PubMed Web of Science ®Google Scholar
• KramerBKRessKMErleyCMPharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failureEur J Clin Pharmacol1992438581505616
   PubMed Web of Science ®Google Scholar
• LeverAFHarrapSBEssential hypertension: a disorder of growth with origins in childhood?J Hypertens199210101201313473
   PubMed Web of Science ®Google Scholar
• LindholmLHCarlbergBSamuelssonOShould beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLancet200536615455316257341
   PubMed Web of Science ®Google Scholar
• LithellHPollareTVessbyBMetabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patientsBlood Press19921921011366265
   PubMedGoogle Scholar
• MacMahonSPetoRCutlerJBlood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasLancet1990335765741969518
   PubMed Web of Science ®Google Scholar
• MacMahonSRodgersANealBBlood pressure lowering for the secondary prevention of myocardial infarction and strokeHypertension19972953789040434
   PubMed Web of Science ®Google Scholar
• Maitland-van der ZeeAHKlungelOHKloostermanJMThe association between antihypertensive drug therapies and plasma lipid levels in the general populationJ Hum Hypertens200115701511607800
   PubMedGoogle Scholar
• MalminiemiKAssociation between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatmentCardiovasc Drugs Ther199592953047662596
   PubMed Web of Science ®Google Scholar
• ManiVVan den MeirackerAHSchalekampMADo beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditionsAm J Hypertens198819162897200
   PubMedGoogle Scholar
• ManciaGDeBGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072511058717563527
   PubMed Web of Science ®Google Scholar
• MarchiFCirielloGEfficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenololAdv Ther1995122122110155349
   PubMedGoogle Scholar
• McTavishDCampoli-RichardsDSorkinEMCarvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacyDrugs199345232587681374
   PubMed Web of Science ®Google Scholar
• MesserliFHAristizabalDSoriaFReduction of left ventricular hypertrophy: how beneficial?Am Heart J1993125152048480623
   PubMedGoogle Scholar
• MesserliFHGrossmanEbeta-Blockers in hypertension: is carvedilol different?Am J Cardiol2004937B12B
   PubMed Web of Science ®Google Scholar
• MesserliFHGrossmanEGoldbourtUAre beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic reviewJAMA1998279190379634263
   PubMed Web of Science ®Google Scholar
• MorganTClinical pharmacokinetics and pharmacodynamics of carvedilolClin Pharmacokinet199426335467914479
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic ConditionsHypertension: management of hypertension in adults in primary care: partial update2006LondonRoyal College of Physicians
   Google Scholar
• NeugebauerGGaborMReiffKDisposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extractionJ Cardiovasc Pharmacol199219Suppl 1S142S61378143
   PubMedGoogle Scholar
• OpieLYusufSOpieLHGershBBeta-blocking agentsDrugs for the Heart20056Philadelphia, PensylvaniaW.B. Saunders Company132
   Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med20053534879716079372
   PubMed Web of Science ®Google Scholar
• PackerMControlled-release carvedilol: a concluding perspectiveAm J Cardiol20069867L9L
   PubMedGoogle Scholar
• PollareTLithellHMorlinCMetabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groupsJ Hypertens1989a755192668407
   PubMed Web of Science ®Google Scholar
• PollareTLithellHSelinusISensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patientsBMJ1989b298115272500169
   PubMed Web of Science ®Google Scholar
• Poole-WilsonPASwedbergKClelandJGComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialLancet200336271312853193
   PubMed Web of Science ®Google Scholar
• RobertsWCRecent studies on the effects of beta blockers on blood lipid levelsAm Heart J1989117709142563923
   PubMedGoogle Scholar
• SarafidisPABakrisGLAntihypertensive therapy and the risk of new-onset diabetesDiabetes Care2006a291167916644658
   PubMed Web of Science ®Google Scholar
• SarafidisPABakrisGLAntihypertensive treatment with beta-blockers and the spectrum of glycaemic controlQJM2006b99431616766516
   PubMed Web of Science ®Google Scholar
• SarafidisPABakrisGLAre beta blockers passe for the treatment of hypertension?J Clin Hypertens (Greenwich)2006c82394016596025
   PubMedGoogle Scholar
• SarafidisPABakrisGLDo the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?J Clin Hypertens (Greenwich)2006d8351616687944
   PubMedGoogle Scholar
• SarafidisPABakrisGLMicroalbuminuria and chronic kidney disease as risk factors for cardiovascular diseaseNephrol Dial Transplant2006e2123667416782993
   PubMed Web of Science ®Google Scholar
• SarafidisPABakrisGLState of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertensionJ Clin Hypertens (Greenwich)2008In press
   Google Scholar
• SarafidisPABakrisGLMetabolic effects of beta-blockers: importance of dissociating newer from conventional agentsJ Hypertens2007252495217143201
   PubMedGoogle Scholar
• SarafidisPAKhoslaNBakrisGLAntihypertensive therapy in the presence of proteinuriaAm J Kidney Dis200749122617185142
   PubMed Web of Science ®Google Scholar
• SarafidisPALasaridisAGousopoulosSPrevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa studyJ Hum Hypertens200418623915029221
   PubMedGoogle Scholar
• SchulmanSPWeissJLBeckerLCThe effects of antihypertensive therapy on left ventricular mass in elderly patientsN Engl J Med1990322135062139175
   PubMed Web of Science ®Google Scholar
• SicaDAbeta-Blockers in Hypertension: A Reassessment of the Benefit of Combined alpha-/beta-BlockadeJ Clin Hypertens (Greenwich)200794917978601
   PubMedGoogle Scholar
• StamlerJStamlerRNeatonJDBlood pressure, systolic and diastolic, and cardiovascular risks. US population dataArch Intern Med19931535986158439223
   PubMed Web of Science ®Google Scholar
• TeneroDMHendersonLSBaidooCAPharmacokinetic properties of a new controlled-release formulation of carvedilolAm J Cardiol2006985L16L
   PubMed Web of Science ®Google Scholar
• US Renal Data SystemUSRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States2005Bethesda, MDNational Institute of Diabetes and Digestive and Kidney Diseases
   Google Scholar
• VerdecchiaPAngeliFPittaviniLRegression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patientsItal Heart J200455051015487267
   PubMedGoogle Scholar
• WeberMABakrisGLTarkaEAEfficacy of a once-daily formulation of carvedilol for the treatment of hypertensionJ Clin Hypertens (Greenwich)20068840917170609
   PubMedGoogle Scholar
• WeissRNebivolol: a novel beta-blocker with nitric oxide-induced vasodilatationVasc Health Risk Manag20062303817326335
   PubMedGoogle Scholar
• WilliamsBPoulterNRBrownMJGuidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IVJ Hum Hypertens2004181398514973512
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension200443101714638619
   PubMed Web of Science ®Google Scholar
• YoshikawaTPortJDAsanoKCardiac adrenergic receptor effects of carvedilolEur Heart J199617Suppl B8168733065
   PubMedGoogle Scholar